NasdaqCM:SLSBiotechs
Is Uncertain Galinpepimut-S Data Timing Reshaping SELLAS Life Sciences Group’s (SLS) Strategic Story?
Earlier this year, SELLAS Life Sciences Group came under scrutiny after reports that its phase 3 acute myeloid leukemia trial for Galinpepimut-S had reached a key mortality-related milestone without a corresponding company update.
Investor attention has also focused on recently amended executive employment agreements that include enhanced benefits in the event of a takeover, raising questions about potential corporate actions alongside the unresolved trial outcome.
We’ll now explore how the...